The Effect of Disease Modifying Treatment In Multiple Sclerosis Patients

MAY 03, 2017
Amy Jacob


At AAN 2017, Robert Zivadinov, MD, PhD, Professor of neurology, University at Buffalo, discussed the primary findings in the phase 3 randomized, placebo controlled TOPIC study, which focused really on the differences between the two doses (7 and 14mg) of Aubagio and placebo. 


Copyright© MD Magazine 2006-2017 Intellisphere, LLC. All Rights Reserved.